论文部分内容阅读
目的:探讨吡柔比星和丝裂霉素交替灌注预防浅表性膀胱癌复发的临床疗效。方法:将我院收治的浅表性膀胱癌患者60例随机分为观察组和对照组各30例,观察组给予吡柔比星和丝裂霉素交替灌注,对照组仅给予丝裂霉素灌注,比较2组患者的复发率。结果:观察组1、2、3年复发率分别为3%、6%、10%;对照组1、2、3年复发率分别为、10%、16%、23%;观察组与对照组不良反应发生率分别为10%、20%,2组比较,观察组均明显低于对照组,差异均具有统计学意义(P<0.05)。结论:吡柔比星和丝裂霉素交替灌注预防浅表性膀胱癌复发疗效显著,比单用吡柔比星更容易耐受,不良反应小,值得临床推广和应用。
Objective: To investigate the clinical efficacy of alternate infusion of pirarubicin and mitomycin in preventing recurrence of superficial bladder cancer. Methods: 60 patients with superficial bladder cancer treated in our hospital were randomly divided into observation group and control group, 30 cases each. The observation group was given pirarubicin and mitomycin alternately, and the control group was given only mitomycin. Perfusion, comparing the recurrence rate of the two groups of patients. Results: The recurrence rates in the observation group at 1, 2, and 3 years were 3%, 6%, and 10%, respectively; the recurrence rates in the control group at 1, 2, and 3 years were 10%, 16%, and 23%, respectively; the observation group and the control group. The incidence of adverse reactions was 10% and 20% respectively. Compared with the two groups, the observation group was significantly lower than the control group, and the difference was statistically significant (P<0.05). Conclusion: The alternate infusion of pirarubicin and mitomycin can prevent the recurrence of superficial bladder cancer. It is more easily tolerated than pirarubicin alone, and has less adverse reactions. It is worthy of clinical application and promotion.